Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.
Affini-T Therapeutics has raised $175.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in March 2022.
Affini-T Therapeutics's investors include Catalio Capital Management, Vida Ventures, Alexandria Venture Investments, Agent Capital, Fred Hutchinson.
Affini-T Therapeutics is headquartered in Watertown, United States.
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer.
Affini-T Therapeutics is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Affini-T Therapeutics — Funding & Investors." VCBacked, March 22, 2022, https://www.vcbacked.co/company/affini-t-therapeutics. Accessed August 13, 2026.
VCBacked. (2022). Affini-T Therapeutics — Funding & Investors. Retrieved August 13, 2026, from https://www.vcbacked.co/company/affini-t-therapeutics
{{cite web |title=Affini-T Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/affini-t-therapeutics |website=VCBacked |access-date=August 13, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated